A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.
Richter, an assistant professor of medicine at the Tisch Cancer Institute at the Ichan School of Medicine in Mt. Sinai Hospital located in New York City, noted that there are always exceptions to this rule, but the standard of care is to keep patients with multiple myeloma to continue therapy long term.
This standard of care, however, presents unique challenges and questions for newly diagnosed patients about to undergo treatment. In an interview during the 2019 CURE Educated Patient Summit on Multiple Myeloma in Charlotte, North Carolina, Richter had the chance to address the key aspects of a multiple myeloma diagnosis and how he addresses common questions from patients.
CURE: What does transplant eligible and transplant ineligible mean for patients?
Richter: The notion of transparent eligibility in the U.S. is not clearly defined. One of the people who trained me used to say, Do the patients have the tiger? relating back to Rocky, and essentially what this means is people who are younger tend to be more eligible. So, are you able to undergo the intensive nature of that procedure and chemotherapy?
If you're younger and healthier, you're generally transplant eligible. As you get older, with more medical problems, it becomes more of a risk. Everything in medicine from a Tylenol to a transplant has a risk and benefit. If you are 105 years old and had a heart attack last week, you're not going to be eligible. If you're 40 and otherwise healthy, you're eligible and everywhere in between is an evaluation of risks and benefits.
How would you describe the standard of care for patients with multiple myeloma?
In general, the standard of care is to attempt to get people onto three drugs. The three drugs usually mean a steroid, and then either an immunomodulatory drug, a proteasome inhibitor or a monoclonal antibody, and using those different combinations to come up with two or three-drug combinations, and actually in some cases four-drug combinations.
The general discussion of which one makes sense is we generally try to put some on a three-drug combination and the two most common ones now VRd (Velcade, Revlimid, and dexamethasone) is really a very big standard approach. There's some really wonderful, emerging data from the MAIA study, looking at taking Revlimid and dexamethasone and adding Darzalex (daratumumab) as a three-drug regimen for people who are not going on to transplant and some of that data looks amazing.
But for the most part, the precision that we use has to do not so much with the tumor but with the patient. Meaning for some diseases, the precision in the upfront setting is we look at a genetic marker and we target that. But for myeloma our upfront choice of therapy is saying, what are your comorbidities? What are your risks? For someone who has neuropathy, we may avoid Velcade. Someone has heart issues, we may avoid carfilzomib (Kyprolis) and if someone has difficult coming back and forth for long infusions, we may avoid Darzalex. So, most of the precision that we use is custom tailoring it not necessarily to the disease upfront, although that's part of it, but also to the patient.
What is the role of stem cell transplantation in treating patients with multiple myeloma?
The role of transplant is constantly evolving in myeloma. A generation ago, when we didn't have very good drugs, transplant was clearly the best thing to do because we didn't have good medicines. Transplant was the only way to get deep and durable remissions. Nowadays that we have such better therapies and even better ones along the way, it's being called into question about how much do we still need transplant. And it's a case by case basis, some people still clearly benefit from transplant.
It's an important discussion to have with your provider. But the risks have been well established for many years and we know how to manage them very well. Although there are risks for it, they're generally consolidated into a couple weeks to a couple of months, as opposed to being on long term treatment that can have ongoing risk of side effects. So, yes, they may be higher, but it's usually for a self-contained amount of time.
It's still a very important tool in our armamentarium to treat patients. Now, that being said, the majority of patients in the United States do not receive autologous transplant, so only about 30% and part of the reason has to do with the age of patients. The average age of a myeloma patient in the U.S. is 69, and many people in their 70s and 80s have other medical problems that make them not eligible for transplant.
There are some socioeconomic reasons, as well as referral patterns and access to care. I live in New York City, you can throw a rock and hit a transplant center, but there are parts of the country where the closest transplant center is hours and hours and hours away. And if you are older, sick or don't have easy transportation, it may be more difficult. So, many people do not receive transplant. However, many people nowadays may not even need it because our drugs have gotten so much better.
Here is the original post:
Understanding the Key Aspects of a Multiple Myeloma Diagnosis - Curetoday.com
- Michael Everest DeMarco Is Advancing Medical Education By Sponsoring Ground-Breaking Research - Yahoo Finance - February 28th, 2020
- Family Doctors: Their Role, Education and Responsibilities - The Hear UP - February 28th, 2020
- Be a Bone Marrow Hero - University of Utah Health Care - February 26th, 2020
- R3 Stem Cell Heroes Program Performs Complimentary Regenerative Therapies on 70 Veterans in 2019 - PR Web - February 26th, 2020
- PROGRESS 2020: Business briefs - The Times - February 26th, 2020
- Mum meets the stem cell donor who saved her four-year-old son's life - Nottinghamshire Live - February 26th, 2020
- Cumberland County family turns to non-FDA approved stem cell treatment to help two-year-old son with cerebral palsy - FOX43.com - February 24th, 2020
- 34 years with a new heart and counting - MDJOnline.com - February 24th, 2020
- Lil Nas X surprises the kids at Berts Big Adventure 2020 - Atlanta Journal Constitution - February 24th, 2020
- The Top BioHealth Capital Region CEOs to Follow on Social Media - BioBuzz - February 24th, 2020
- Local News: Calculating the costs of beef production (2/19/20) - Monett Times - February 24th, 2020
- Stem Cell Therapy Market Competitive Analysis and Forecast 2017-2025 - News Parents - February 22nd, 2020
- Survivor Legend Ethan Zohn Discusses His Journey Through Cancer and Back to the Island - Parade - February 20th, 2020
- Lawyer thought her tiredness was down to jet lag until she visited doctor - Mirror Online - February 19th, 2020
- Family honors the memory of loved one by collecting teddy bears for families dealing with cancer - KTIV - February 18th, 2020
- Transplanting the immune system: Easier on patients than medication? - WNDU-TV - February 18th, 2020
- FHSU partners with Be the Match for bone marrow registry event - hays Post - February 18th, 2020
- Coronavirus: Doctors try 3,000-year-old Traditional Chinese Medicine (TCM) to treat the virus - Times of India - February 18th, 2020
- Indian doctors fix Yemeni man's face in rare reconstructive surgery - The New Indian Express - February 16th, 2020
- Recent AI Developments Offer a Glimpse of the Future of Drug Discovery - Tech Times - February 16th, 2020
- Niagara walkers support 'Rainbow in the storm of cancer' - Niagarathisweek.com - February 16th, 2020
- Stem Cell Therapy Market Statistics, Trends, Size, Growth Opportunities, Share Demand and Forecast to 2025 - Jewish Life News - February 11th, 2020
- Why this Island woman is giving part of her liver to a complete stranger - Yahoo News Canada - February 11th, 2020
- The life and controversial career of radio host Rush Limbaugh - Business Insider - Business Insider - February 11th, 2020
- Patients guide to stem cell treatments top 10 list ... - February 10th, 2020
- No system is perfect, multi-disciplinary approach will benefit cancer patients: Ayurvedic physician - The New Indian Express - February 9th, 2020
- There's no place like home - The Winchester Star - February 9th, 2020
- This World Cancer Week, let's separate the myth and reality surrounding it - The New Indian Express - February 9th, 2020
- Report: Former Intercontinental Champion Working To Return To WWE Ring - Cultaholic - February 7th, 2020
- Life and death in Wuhan: On the front lines fighting coronavirus - Nikkei Asian Review - February 7th, 2020
- First CAR-T cell cancer therapy patient in Delaware - Dover Post - February 6th, 2020
- Immune therapy tweak offers new hope to blood cancer patients - NBC News - February 6th, 2020
- Stem Cell Therapy Market Trends and Growth, Outlook, Research, Trends and Forecast to 2025 - Instant Tech News - February 6th, 2020
- 4-year-old thalassemia surivor meets lifesaver for first time - Devdiscourse - February 6th, 2020
- Cell Harvesting Market Report On Competitive Landscape, Key Players, Future Developments and Growth 2025 - Dagoretti News - February 6th, 2020
- Four-year-old girl meets stem cell donor for the first time in Bengaluru - The Hindu - February 5th, 2020
- 4-year-old thalassemia surivor meets lifesaver for first time - Yahoo India News - February 5th, 2020
- Huey Lewis May Never Perform Again. But He Refuses to Give Up - Rolling Stone - February 5th, 2020
- Kochi to host first ever global meet on Integrative Oncology - Onmanorama - February 5th, 2020
- [World Cancer Day] 5 women from Bollywood whose struggles with cancer are truly inspirational - YourStory - February 5th, 2020
- Son to shave head to support mum with leukaemia - Chronicle - February 5th, 2020
- Meet the 21-year-old who turned her love for animals into a successful petcare business - YourStory - January 31st, 2020
- On Holocaust Remembrance Day, the stories of two Jewish scientists - Massive Science - January 31st, 2020
- Lessons Learned on Listening to the Dying, World Cancer Day Reflections - MissionsBox - January 31st, 2020
- Snake venom can now be made in a lab and that could save many lives - KTVZ - January 29th, 2020
- Stem Cell Therapy Market Predicted to Accelerate the Growth by 2017-2025 - Jewish Life News - January 29th, 2020
- Colleagues are registering as donors and raising funds to help Trowbridge firefighter Guy Tadman and the charities supporting him - Wiltshire Times - January 29th, 2020
- If you want to ban fetal tissue research, sign a pledge to refuse its benefits - USA TODAY - January 27th, 2020
- Scots tot, 3, battling rare blood cancer to receive stem cell donations from anonymous American woman - The Scottish Sun - January 27th, 2020
- Scots toddler who needs weekly blood transfusions to receive life changing stem-cells from US donor - Daily Record - January 27th, 2020
- Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - APN News - January 27th, 2020
- How to Improve on a Good Year for Global Health | by Melvin Sanicas - Project Syndicate - January 27th, 2020
- Sentencing rescheduled in case connected to Indy doctor's murder - WTHR - January 26th, 2020
- Blood drive to honor Franklin child with cancer - Daily Journal - January 24th, 2020
- UAB scientist studies aging through gray hair, says hair could be rejuvenated - AL.com - January 24th, 2020
- Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - MENAFN.COM - January 24th, 2020
- How will technology shape and disrupt our health care this decade? - Times Union - January 24th, 2020
- Major name scheduled to be in Houston for WWE Royal Rumble PPV - Wrestling News - January 24th, 2020
- LifeCell launches 'Genome-Scope' newborn genetic testing to diagnose over 4000 genetic conditions - Yahoo India News - January 24th, 2020
- Advancells Group, IFC concluded their three-day workshop on Regenerative Medicine - Yahoo India News - January 24th, 2020
- New York-based hair restoration company opens new office in New Jersey - amNY - January 24th, 2020
- Orgel, others push city for help with loss of HealthPlus pool - Auburn Villager - January 24th, 2020
- Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - Business Wire India - January 23rd, 2020
- Biodegradable tube excels at treatment of nerve injuries - New Atlas - January 23rd, 2020
- European Commission Approves Darzalex (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diag -... - January 23rd, 2020
- Breakthrough discovery could lead to one-size-fits-all cancer treatment - The Independent - January 23rd, 2020
- Illumia Therapeutics, Singapore's Latest Full-Service Medispa, Lets You Address Your Beauty And Wellness Needs In One Place - Singapore Tatler - January 23rd, 2020
- Misplaced Assumptions, Where Investments Go Wrong - Seeking Alpha - January 23rd, 2020
- Learning to be relentless - The Daily Republic - January 19th, 2020
- Here's Why Stemline Therapeutics Dropped Today - Motley Fool - January 19th, 2020
- Medics key to spotting signs of child abuse, Abu Dhabi conference hears - The National - January 19th, 2020
- Smart Group & A4M Concluded their First India Conference 2020 - NewsPatrolling - January 19th, 2020
- 'Comfort' or con? Despite money, education, well-off Filipinos turning to questionable treatments - Coconuts - January 13th, 2020
- Doctor's Hospital focused on incorporation of AI and machine learning - EyeWitness News - January 13th, 2020
- Viewpoints: Medicaid Expansion Reveals How Liberal Policies Make For Good Politics; Hey, Congress, What's The Hold Up With Surprise Medical Bills? -... - January 13th, 2020
- White blood cells: Function, ranges, types, and more - Medical News Today - January 10th, 2020
- Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases - PRNewswire - January 10th, 2020
- Tip Sheet: Mesh loaded with T cells shrinks tumors; second dose of CAR-T cells shows potential; and gene-edited cells stay safe as immunotherapy... - January 10th, 2020
- 3D-printed Organs Give Hope to Transplant Patients Now. Powered by - Now. Powered by Northrop Grumman. - January 10th, 2020
- Seattle Childrens faces widening array of lawsuits over fatal mold infections - Seattle Times - January 10th, 2020